# MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

> **NCT06969781** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DEVICE:** MWA
- **DRUG:** TKI

## Key facts

- **NCT ID:** NCT06969781
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969781, "MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06969781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*